When did Biodexa Pharmaceuticals' stock split?

Biodexa Pharmaceuticals's stock reverse split before market open on Monday, March 27th 2023. The 1-4 reverse split was announced on Monday, March 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of Biodexa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biodexa Pharmaceuticals investors own include CRISPR Therapeutics (CRSP) , Corbus Pharmaceuticals (CRBP) , Pfizer (PFE) , Vaxart (VXRT) , Nabriva Therapeutics (NBRV) , Novavax (NVAX) , Plug Power (PLUG) , SCYNEXIS (SCYX) , Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE) .

NASDAQ:MTP

Biodexa Pharmaceuticals (MTP) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free MTP Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.29
▼
$3.22
52-Week Range: N/A

Volume: 164,300 shs
Average Volume: 57,354 shs
Market Capitalization: $6.18 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Biodexa Pharmaceuticals alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Biodexa Pharmaceuticals Stock (NASDAQ:MTP)

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MTP Stock News Headlines

March 28, 2024 | benzinga.com

Extend Life Expectancy Against Aggressive Brain Cancers - Nano-Cap Firm Biodexa's Investigational Drug Shows Potential

March 28, 2024 | investorplace.com

Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 106% Today?

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

February 23, 2024 | msn.com

Biodex stock slides 7% amid data for two drug studies

February 13, 2024 | msn.com

Why Is Brain Cancer Focused-Biodexa Pharmaceuticals Stock Trading Higher Today?

December 19, 2023 | msn.com

Crude Oil Rises Over 1%; Biodexa Pharmaceuticals Shares Plunge

December 19, 2023 | tmcnet.com

Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering

July 8, 2023 | benzinga.com

Biodexa Pharmaceuticals PLC Announces Results Of Appeal Of Delisting Determination

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 25, 2023 | seekingalpha.com

BDRX Biodexa Pharmaceuticals Plc

April 4, 2023 | finance.yahoo.com

Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity

March 28, 2023 | investorplace.com

Why Is Midatech Pharma (BDRX) Stock Up 64% Today?

February 9, 2023 | finance.yahoo.com

Midatech Pharma PLC Announces Private Placement Raising US $6.0 million

January 23, 2023 | financialpost.com

Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc

January 12, 2023 | finance.yahoo.com

Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Study

January 3, 2023 | finance.yahoo.com

BIOAF: Merger with Midatech Pharma

December 13, 2022 | finance.yahoo.com

Midatech Pharma PLC Announces Proposed Acquisition of Bioasis Technologies Inc

December 13, 2022 | finance.yahoo.com

Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc

October 11, 2022 | seekingalpha.com

MTP Midatech Pharma plc

September 14, 2022 | marketwatch.com

Midatech Pharma Will Need Extra Financing in 1Q 2023; Mulling Options

September 14, 2022 | finance.yahoo.com

Midatech Pharma PLC Announces ADR Ratio Change

August 3, 2022 | thestreet.com

Midatech Pharma PLC News

June 21, 2022 | finance.yahoo.com

Midatech Pharma PLC Announces MTX110 Development for the Treatment of Glioma

June 10, 2022 | yahoo.com

Midatech Pharma PLC - MTX110 Study to be Presented at ISPNO 2022

June 7, 2022 | uk.investing.com

Midatech Pharma: MTX110’s Path To Market Fast-Tracked In RGBM

June 1, 2022 | seekingalpha.com

Midatech Pharma climbs on FDA’s Fast Track Designation for brain tumor candidate

June 1, 2022 | finance.yahoo.com

Midatech's investigational glioblastoma treatment gets Fast Track status

See More Headlines

Receive MTP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MTP
CUSIP: N/A
CIK: 1643918
Web: www.midatechpharma.com
Phone: 441235888300
Fax: N/A
Employees: 18
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $800,000.00
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.67 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 21,670,000
Free Float: 21,595,000
Market Cap: $6.18 million
Optionable: Not Optionable
Beta: 2.29

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Stephen Anthony Stamp
Chief Executive Officer, CFO, Secretary & Director
Dmitry Zamoryakhin
Chief Scientific Officer
Dan Palmer
Vice President-Technology
Steve Ellul
Vice President-Business Development
Fiona Sharp
Group Financial Controller

Key Competitors

View All Competitors

MTP Stock Analysis - Frequently Asked Questions

When did Biodexa Pharmaceuticals' stock split?: Biodexa Pharmaceuticals's stock reverse split before market open on Monday, March 27th 2023. The 1-4 reverse split was announced on Monday, March 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.
What other stocks do shareholders of Biodexa Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Biodexa Pharmaceuticals investors own include CRISPR Therapeutics (CRSP), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), Vaxart (VXRT), Nabriva Therapeutics (NBRV), Novavax (NVAX), Plug Power (PLUG), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE).

This page (NASDAQ:MTP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Biodexa Pharmaceuticals (MTP) Stock Price, News & Analysis

About Biodexa Pharmaceuticals Stock (NASDAQ:MTP)

MTP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

MTP Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info